Pharmacogenomics Tests - Galaxi Genomics

Pharmacogenomics (PGx) Testing for Safer, Smarter Chemotherapy

At Galaxi Genomics, we help oncologists optimise chemotherapy dosing and reduce severe toxicities through precision pharmacogenomics (PGx) testing.

Why Pharmacogenomics Testing?

Up to 30% of patients experience severe adverse drug reactions (ADRs) from chemotherapy due to genetic variations.

Prevent life-threatening toxicities (e.g., neutropenia, diarrhea, myelosuppression).

Personalize drug dosing based on genetic metabolism profiles.

Improve treatment adherence by minimizing unnecessary side effects.

Our PGx Tests for Oncology

DPYD Testing – Assess critical fluoropyrimidine metabolism variants.

Comprehensive Onco-Pharmacogenomics Panel – Full germline variant analysis for optimised chemotherapy safety and efficacy.

DPYD + NUDT15 + TPMT – Expanded coverage for thiopurine therapies.

Who Should Be Tested?

PGx testing is recommended for all patients before initiating:

DPYD Testing: Recommended for patients before starting fluoropyrimidines (5-FU, capecitabine) for various cancers.

NUDT15 & TPMT Testing: Recommended for patients before initiating thiopurines (6-MP, azathioprine, thioguanine).

UGT1A1 Testing: Recommended before starting irinotecan, particularly for colorectal and pancreatic cancers.

CYP2D6 Testing: Used to inform tamoxifen therapy for hormone receptor-positive breast cancer.

Why Choose Our PGx Testing?

Evidence-Based

Aligns with FDA, CPIC guidelines.

Cost-Effective

Reduces hospitalizations from preventable toxicities.

Seamless Integration

EHR-compatible reports for easy implementation.

Why Work With Galaxi Genomics?

Precision Genomics, Powered by Rigorous Science

At Galaxi Genomics, we combine cutting-edge NGS technology with advanced analytics to deliver clinically actionable genomic insights—helping physicians make confident, evidence-based treatment decisions.

ACMG/AMP Compliant Variant Classification

Strict adherence to clinical guidelines for consistent, reliable variant interpretation.

AI & Statistical Evidence-Driven Refinement

Enhance variant assessment with machine learning and population genomics for higher accuracy.

Actionable Reports for Clinicians

Clear, therapy-focused insights with evidence strength, drug associations, and clinical guidance.

Oncologist-Validated Solutions

Collaborate with oncologists to refine and validate genomic-based treatment strategies.

Fast, Impactful Results

Optimized workflows ensure rapid turnaround without compromising precision.

Comprehensive Evidence Backing

Leverage literature, global genomic databases, and population studies to reinforce test reliability.